Literature DB >> 10952322

Postinfarct refractory right ventricle: right ventricular exclusion. A possible option to mechanical cardiac support, in patients unsuitable for heart transplant.

T K Kaul1, D R Kahn.   

Abstract

BACKGROUND: Postbypass refractory right ventricle (RRV) may develop due to right ventricular (RV) ischemia or infarction. In cases with RV infarction, recovery is often prolonged and salvage rate is extremely poor. In this retrospective study, we have examined the role of right ventricular exclusion (RVE), as a possible option to conventional weaning or bridging to heart transplant (B-HTX), in patients who were unsuitable for heart transplant.
METHODS: During last 5 years, cumulative incidence of postbypass refractory circulatory failure (RCF) in our adult patients was 0.39% (26/6542). This problem was caused by a RRV in 17 (65%) patients. After CABG, these patients developed a grossly distended and poorly contracting RV (RVEDV: 330-400 ml, RVEF: 0-10%), high central venous pressure (> or =18 mmHg) and an inadequate aortic pressure for weaning off cardiopulmonary bypass. Three patients, who were unacceptable for HTX under UNOS program (age >65 years), were weaned off bypass after RVE, and remaining patients with RVAD (n=3) or BiVAD support, depending upon their concomitant moderate or poor left ventricular performance.
RESULTS: The significant predictors of RRV by univariate analysis were; 2nd or 3rd redo CABG for a recent myocardial infarction, and failed graft angioplasty. Hospital mortality (14-60 days) was 0/3, 3/3 and 3/11 for the patients weaned off with RVE, RVAD and BiVAD respectively. At 3 years, overall salvage rate was 9/17 (RVE: 3/3, BiVAD B-HTX 4/6 + 2 weaned with BiVAD support).
CONCLUSION: Right ventricular exclusion is a possible option to conventional B-HTX with mechanical support, in patients who develop postinfarct RRV and are unsuitable for transplant.

Entities:  

Mesh:

Year:  2000        PMID: 10952322

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  7 in total

Review 1.  Management of pulmonary hypertension and right heart failure in the intensive care unit.

Authors:  Jonathan Grinstein; Mardi Gomberg-Maitland
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

Review 2.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

Review 3.  Management of acute right ventricular failure in the intensive care unit.

Authors:  Eric M Green; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2012-09

4.  In-silico assessment of the effects of right ventricular assist device on pulmonary arterial hypertension using an image based biventricular modeling framework.

Authors:  Sheikh Mohammad Shavik; Liang Zhong; Xiaodan Zhao; Lik Chuan Lee
Journal:  Mech Res Commun       Date:  2019-04-15       Impact factor: 2.254

5.  Feasibility and efficacy of bypassing the right ventricle and pulmonary circulation to treat right ventricular failure: an experimental study.

Authors:  Jan Spillner; Christian Stoppe; Nima Hatam; Andrea Amerini; Ares Menon; Christoph Nix; Ulrich Steinseifer; Yousef Abusabha; Hanna Giessen; Rüdiger Autschbach; Marcus Haushofer
Journal:  J Cardiothorac Surg       Date:  2012-02-06       Impact factor: 1.637

6.  Acute pressure overload of the right ventricle. Comparison of two models of right-left shunt. Pulmonary artery to left atrium and right atrium to left atrium: experimental study.

Authors:  Mihalis Argiriou; Dimitrios Mikroulis; Timothy Sakellaridis; Vasilios Didilis; Apostolos Papalois; George Bougioukas
Journal:  J Cardiothorac Surg       Date:  2011-10-19       Impact factor: 1.637

7.  Hemi-fontan or bidirectional cavopulmonary shunt for right ventricular failure after mitral valve replacement and acute ascending aortic dissection: report of two cases.

Authors:  Hassan Teimouri; Feridoun Sabzi; Babak Nasiri
Journal:  J Tehran Heart Cent       Date:  2013-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.